Menarini Industrie Farmaceutiche Riunite: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Ob
NewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending EU marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing LDL-C reductions up to 40% and about 50%. The European Commission decision is expected in 2H26.
How this was made
The 30-second read
Why it matters
This is a regulatory de-risking step toward EU commercialization, with the European Commission expected to issue the final centralized marketing authorization decision in 2H26. The milestone also ties to Menarini’s exclusive European commercialization rights and NewAmsterdam’s tiered royalties.
Market read
Traders can update approval-probability assumptions and timeline expectations for obicetrapib in Europe based on today’s CHMP positive opinion.
What to watch
The article does not address label specifics, safety findings beyond tolerability comparable to placebo, or any EC-requested post-CHMP conditions that could affect launch timing and uptake.
Background
NewAmsterdam and Menarini announced a positive CHMP opinion from EMA for marketing authorization of obicetrapib monotherapy (Ubeslo) and an obicetrapib/ezetimibe fixed-dose combination (Evlarco) for primary hypercholesterolemia.
Ticker impact
NewAmsterdam reports a positive CHMP opinion recommending marketing authorization for Ubeslo and Evlarco in Europe, with EC decision expected in 2H26.
Likely positive near-term sentiment, with follow-through dependent on EC review outcome and any additional regulatory questions.
A positive CHMP opinion is a concrete regulatory milestone and the article provides a clear next decision window (2H26) plus commercialization rights and royalty economics.
Market effects
Supports sentiment for CETP inhibitor and non-statin LDL-C lowering pipelines, potentially improving read-through for similar late-stage programs.
Improves odds of earlier European access to obicetrapib-based therapies, affecting EU cardiometabolic treatment competition.
May influence global investor perception of CETP inhibitor viability, though the decision is specifically for Europe.
Counterpoint
A CHMP positive opinion is not final approval; EC review could still delay or require additional data, so the market may overprice the probability of approval.
Key entities
- companyNewAmsterdam Pharma Company N.V.
Nasdaq-listed late-stage biopharmaceutical developing obicetrapib for LDL-C lowering and residual cardiovascular risk.
- companyMenarini Group
Partner with exclusive commercialization rights for obicetrapib in Europe and responsible for regulatory interactions and commercialization.
- regulatorEMA CHMP
Committee for Medicinal Products for Human Use that adopted the positive opinion recommending marketing authorization.
- regulatorEuropean Commission
Expected to adopt the final decision on marketing authorization in 2H26.
